UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 6, 2004
Date of Report (Date of earliest
event reported)
NEORX CORPORATION
(Exact Name of Registrant as Specified in Charter)
Washington | | 0-16614 | | 91-1261311 |
(State or Other Jurisdiction of Incorporation) | | (Commission File No.) | | (IRS Employer
Identification No.) |
| | | | |
300 Elliott Avenue West, Suite 500, Seattle, Washington 98119-4114 |
(Address of principal executive offices) (Zip Code) |
| | | | |
(206) 281-7001 |
(Registrant’s telephone number, including area code) |
Item 5. Other Events
NeoRx announced that it has filed an Investigational New Drug application with the US Food and Drug Administration for a phase II clinical study of STR™ (Skeletal Targeted Radiotherapy) in patients with breast cancer that has metastasized to the bone. See press release dated July 6, 2004 attached to this report as Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit No. | | Description | |
| | | |
99.1 | | Press release dated July 6, 2004 | |
| | | |
| | | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NEORX CORPORATION |
| (Registrant) |
| |
Date: July 8, 2004 | By: | /s/ MICHAEL K. JACKSON |
| Michael K. Jackson |
| Corporate Controller and Chief Accounting Officer |
3
EXHIBIT INDEX
| | Description |
| | |
99.1 | | Press release dated July 6, 2004 |
| | |
| | |
| | |
4
